Advancing vaccines for better lives
Valneva (valneva.com) scores 85 out of 100 on Brand Analyzer, placing it in the Strong Brand tier among Healthcare brands, in the 92nd percentile of 13409 Healthcare brands.
Valneva is a French specialty vaccine company headquartered in Saint-Herblain, founded in 2013. It develops, manufactures, and commercializes prophylactic vaccines targeting infectious diseases with significant unmet medical needs. The company has commercialized three vaccines, including a single-shot chikungunya vaccine, and maintains a clinical pipeline that includes candidates for Lyme disease and Shigella. Its customers include healthcare providers, public health organizations, governments, and travelers.
| Brand Name | Valneva |
|---|---|
| Domain | valneva.com |
| Industry | Healthcare |
| Founded | 2013 |
| Headquarters | Saint-Herblain |
| Main Competitors | GSK (83/100), Sanofi (90/100), Pfizer (89/100), Moderna (94/100), Bavarian Nordic (83/100), Emergent BioSolutions (80/100), Merck (81/100) |
Moz Domain Authority 59/100 vs category average 41 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #240,837 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
Valneva has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "Valneva is a specialty vaccine company focused on preventing infectious diseases with significant unmet medical needs." (Meta description: 16 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Apache, WordPress, Ghost.
Social footprint: verified profiles on X (Twitter), LinkedIn, Facebook, YouTube, Instagram; no detected presence on GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked September 2026.
When asked "What is Valneva?", Claude could identify the brand as of September 2026. Valneva is a French-Austrian specialty vaccine company that develops, manufactures, and commercializes vaccines for infectious diseases with unmet needs, including its inactivated Japanese encephalitis vaccine Ixiaro and its chikungunya vaccine Ixchiq, the first approved vaccine Best known for Developing Ixchiq, the world's first approved chikungunya vaccine, and its Japanese encephalitis vaccine Ixiaro.
When asked "Best brands similar to Valneva?", Claude would recommend Valneva as of September 2026. It's a notable specialty vaccine maker with unique approved products in niche infectious disease areas, making it relevant when discussing vaccine developers beyond the big pharma players.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Valneva's main competitors in Healthcare: GSK (83/100), Sanofi (90/100), Pfizer (89/100), Moderna (94/100), Bavarian Nordic (83/100).
Sources: Brand Analyzer scan
Valneva offers prophylactic vaccines targeting infectious diseases with significant unmet medical needs. Its commercialized portfolio includes three vaccines, notably a single-shot chikungunya vaccine. The company also has a pipeline of vaccine candidates in clinical development, including ones for Lyme disease and Shigella.
Sources: Valneva official site
Valneva is a French specialty vaccine company headquartered in Saint-Herblain, founded in 2013. It focuses on developing, manufacturing, and commercializing prophylactic vaccines to prevent infectious diseases that lack adequate existing solutions.
Sources: Valneva official site
Valneva has moderate AI-search visibility, scoring 60/100 on Brand Analyzer's AI visibility composite (visibility 70, trust 40, recommendation 65). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Valneva official site
Valneva was founded in 2013. Valneva operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Valneva is headquartered in Saint-Herblain. Valneva operates in the Healthcare category.
Sources: Wikidata
Valneva develops, manufactures, and commercializes vaccines aimed at preventing infectious diseases with significant unmet medical needs. It has successfully brought three vaccines to market, including a single-shot chikungunya vaccine, and advances a pipeline of additional candidates, such as vaccines for Lyme disease and Shigella, through clinical development.
Sources: Valneva official site
Valneva scores 65/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: Valneva official site
Valneva is known for developing and commercializing a single-shot chikungunya vaccine, one of three vaccines it has brought to market. It is also recognized for advancing clinical-stage candidates targeting diseases such as Lyme disease and Shigella.
Sources: Valneva official site
Valneva can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Valneva official site
Valneva's vaccines and pipeline are aimed at healthcare providers, public health organizations, governments, travelers, and patients seeking protection against infectious diseases such as chikungunya, Lyme disease, and Shigella.
Sources: Valneva official site
Valneva scores 60/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Valneva has a moderate AI-visibility profile at 60/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (70/100) and its weakest is trust (40/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a global traffic rank of #240,837 (Tranco). The main gaps holding it back: thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Valneva from memory (September 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Valneva: UV Skinz (85/100), Uqora (85/100), Varian (85/100), Vera Clinic (85/100).
A step up - brands to learn from: Zoetis (91/100), theSkimm (91/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.